Compare DSP & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | LUCD |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 183.5M |
| IPO Year | 2021 | 2021 |
| Metric | DSP | LUCD |
|---|---|---|
| Price | $12.41 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $18.11 | $3.94 |
| AVG Volume (30 Days) | 188.5K | ★ 727.2K |
| Earning Date | 06-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 16.67 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $344,201,000.00 | $4,346,000.00 |
| Revenue This Year | $16.52 | $7.69 |
| Revenue Next Year | $16.62 | $155.47 |
| P/E Ratio | $35.00 | ★ N/A |
| Revenue Growth | 19.00 | ★ 79.00 |
| 52 Week Low | $8.11 | $0.95 |
| 52 Week High | $16.25 | $1.80 |
| Indicator | DSP | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 68.06 | 51.07 |
| Support Level | $12.32 | $1.01 |
| Resistance Level | $13.20 | $1.52 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.37 | -0.01 |
| Stochastic Oscillator | 85.08 | 7.07 |
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.